Introduction: The proven pathological alterations in the kynurenine pathway of tryptophan metabolism, either in preclinical models of neurological and psychiatric disorders or in human samples themselves, elicited numerous attempts to restore the altered balance via pharmaceutical manipulation of the pathway. Areas covered: The aim of the authors was to conduct a review of relevant scientific data on enzyme inhibitors of the kynurenine pathway, with special attention to pipeline drug development strategies based on relevant patent literature, covering the period of 2012-2015. Considering the magnitude of the topic, only the most prominent examples of lead compounds and substances necessary to enlighten structure activity relationships were reported. Expert opinion: Although the clinical and preclinical data are reassuring, there is a lack of applicable drugs in daily clinical practice. However, the recent determination of enzyme structures considerably promoted the development of potent inhibitors, most of them having been designed as a structural analog of the natural enzyme substrate. Especially, the inhibition of indolamine 2,3-dioxygenase in central nervous system tumors, the inhibition of kynurenine aminotransferase in cognitive dysfunction, and the inhibition of kynurenine 3-monooxygenase in neurodegenerative disorders, such as Huntington's disease, each show great promise.
The kynurenine pathway of tryptophan metabolism
The kynurenine (KYN) pathway is the main route of tryptophan (TRP) metabolism ( Figure 1 ; [1] ), more than 95% of TRP is metabolized through kynurenines. [2] This pathway consists of several neuroactive metabolites and provides the major source of nicotinate [3] for the production of nicotinamide adenine dinucleotide (NAD + )and nicotinamide adenine dinucleotide phosphate (NADP + ) coenzymes. The neuroactive kynurenines include kynurenic acid (KYNA), 3-hydroxy-L-KYN (3-OH-L-KYN), and quinolinic acid (QUIN), and alterations in their levels have proven pathogenic roles in several neurological and psychiatric conditions. [4] KYNA is a wide-spectrum endogenous antagonist of ionotropic excitatory amino acid receptors. [5] In micromolar concentrations, in addition to exerting a weak antagonistic effect on α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) and kainate receptors [6] , it displays competitive antagonism at the strychnine-insensitive glycinebinding site of the N-methyl-D-aspartate receptor (NMDAR; [7] ). In addition to its inhibitory profile, in nanomolar concentrations, it is capable of facilitating AMPAR responses, raising the possibility of partial agonism. [8] Previously, it was believed that despite the above-described broad action at glutamatergic receptors, the main mechanism of action of KYNA on glutamatergic neurotransmission at physiologically relevant nanomolar concentrations would be mediated via the non-competitive blockade of α7-nicotinic acetylcholine receptors at glutamatergic terminals, [9] the activation of which is involved in the regulation of glutamate release. [10] However, the results of the study presented by Hilmas et al. [9] could not be repeated from experiments of four different, independent laboratories, indicating that KYNA may not influence glutamate release via the blockade of α7-nicotinic acetylcholine receptors. [11] [12] [13] [14] These contradictory findings may be attributable to a nonspecific effect produced by dimethyl sulfoxide applied as a solvent for KYNA. Nevertheless other possible reasons, such as regional or species differences, or the age of the preparation could not be accounted for the observed contradictory results. [14] Although it has been reported as well that KYNA can elicit inositol trisphosphate production and Ca 2+ mobilization through the activation of G protein-coupled receptor 35 (GPR35), [15] the role of this phenomenon is questionable as regards the central nervous system (CNS) due to the limited expression of GPR35 in the brain. In addition to acting on cell surface receptors, it is suggested that KYNA can also exert potent free radical scavenging and antioxidant effects. [16] With regard to 3-OH-L-KYN, its deleterious effects are proposed to be mediated by free radicals and not by glutamate receptors. [17] Some of the toxic actions of 3-OH-L-KYN may be attributable to its metabolite, 3-hydroxyanthranilic acid (3-OH-ANA), which readily undergoes auto-oxidation with the production of O 2 -, [18] resulting in neurotoxic properties. [19] QUIN is a weak, but specific competitive agonist with low receptor affinity at the NMDAR subgroup containing GLUN2A and GLUN2B subunits, [20] the latter having a special role in mediating glutamate-induced excitotoxicity. [21] In addition to the direct activation of NMDARs, QUIN can evoke the release and inhibit the uptake of glutamate as well. [22] Furthermore, the production of reactive oxygen intermediates and the induction of lipid peroxidation also contribute to the neurotoxic effects of QUIN. [23] Several neurological conditions can be characterized by the absolute or relative decrease in KYNA concentrations and the elevation of 3-OH-L-KYN and QUIN. [4, [24] [25] [26] However, the excessive elevation of KYNA can also have detrimental effects, such as the impairment of cognitive function in schizophrenia [27, 28] and Alzheimer's disease (AD). [29] [30] [31] In light of the above-mentioned data, there are three main ways of achieving neuroprotection targeting the kynurenine pathway: the prodrug, the KYNA analog, and the metabolic shift concepts. [4] With regard to the metabolic shift concept, many enzyme inhibitors have been developed with the aim of reversing pathological alterations at the level of neuroactive kynurenines. Although the question may arise whether the inhibition of TRP metabolism results in pathological decrease of de novo NAD + biosynthesis, [32] the existence of the salvage pathway most probably provides a sufficient compensation through an appropriate exogenous intake of niacin, especially in light of the fact that deficiency of niacin could result in pellagra, a disease linked to chronic systemic depletion of NAD + .
2. Structure and function of certain enzymes of the kynurenine pathway and their inhibitors as neurotherapeutics 2.1. Indolamine 2,3-dioxygenase 1 and 2, tryptophan 2,3-dioxygenase
The conversion of L-TRP by indolamine 2,3-dioxygenase (IDO, also known as IDO1, EC: 1.13.11.52) and tryptophan 2,3-dioxygenase (TDO, also known as TDO2, EC: 1.13.11.11) enzymes to N-formyl-KYN is the rate-limiting step of the synthesis of L-KYN and the KYN pathway itself. Although IDO1 shares very limited homology with TDO at amino acid level, both enzymes are b-type heme-dependent cytosolic dioxygenases, and their mechanism of action includes the incorporation of two atoms of molecular oxygen into the indole ring of their substrate. [33] Enzyme-structure studies, yielding three-dimensional (3D) models as well, demonstrated that IDO is a monomeric, two-domain enzyme comprising one molecule of heme b, [34] whereas TDO is a tetrameric protein comprising four molecules of heme b. [35, 36] A third, more recently identified tryptophan catabolic enzyme is IDO2 (also known as INDOL1, EC: 1.13.11.-), which is structurally similar to IDO and is encoded adjacently. [37, 38] It is, however, unclear if IDO2 is functionally active in humans, [39, 40] and its relevance in conditions affecting the human neural system has not yet been demonstrated.
IDO is widely expressed in the body including the CNS; however, it is more abundantly expressed in immune cells (especially antigen-presenting cells such as macrophages and dendritic cells) and the placenta. In contrast, TDO is preferentially expressed in the liver. Unlike TDO, IDO is readily inducible by various inflammatory stimuli, including interferon-α (IFN-α), IFN-β, and IFN-γ, interleukin-1 and -2, tumor necrosis factor, cytotoxic T lymphocyte antigen 4, transforming growth factor β, and lipopolysaccharide. [41] The activation of the KYN pathway has in turn immunosuppressive properties, mediated in part via TRP depletion, and the elevated levels of KYN, 3-OH-KYN, 3-OH-ANA, and QUIN, which lead to the suppressed proliferation and increased apoptosis of activated T helper 1 lymphocytes, as well as the increase in the number of regulatory T cells. [4] The immunosuppressive effect of placental IDO activation and downstream kynurenines is thought to be responsible for maternofetal immune tolerance, and its fingerprint in terms of elevated KYN/TRP ratio has recently been evidenced from human umbilical cord vein serum samples. [42] Increased IDO activation has been linked to various neurological and psychiatric disorders where neuroinflammation is implicated at some point of the pathogenesis, including Parkinson's disease, Huntington's disease (HD), AD, multiple sclerosis, amyotrophic lateral sclerosis, cerebral ischemia, CNS infections, and major depression (widely reviewed in [4] ). On the other hand, elevated TDO expression, increased KYNA levels, and elevated kynurenine 3-monooxygenase (KMO) activity have been observed in regions preferentially involved in schizophrenic patients, with increased KYNA and decreased QUIN levels measured in the cerebrospinal fluid, alterations suggested to essentially contribute to the cognitive deficits observed in the disease. [4, 43, 44] The development of cognitive dysfunction via increased KYNA levels may be attributable to its excessive anti-glutamatergic effect, as detailed later.
The high expression of both IDO and TDO has been linked to a variety of tumors (including that formed in the CNS [45, 46] ), and they are thought to be in part responsible for mediating tumor camouflage via providing an immunosuppressive milieu. The role of IDO2 in tumor survival has also recently gained intensive research interest. By far the most extensively examined inhibitor of IDO is the substrate analog 1-methyl-TRP, more specifically its D stereoisomer 1 (1-methyl-D-TRP, also known as indoximod, NLG8189). Interestingly,
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while 1-methyl-L-TRP is far more effective in inhibiting IDO in vitro in cell-free and some cell culture assays (K i = 19 μM), the D stereoisomer is reported to be highly superior among in vivo conditions: it shows anti-tumor effect [47] and it has already been involved in clinical trials as standalone or add-on therapy to boost anti-cancer immunity. [45] In particular, compound 1 is used together with temozolomide in a trial enrolling patients with primary brain malignancies (NCT02052648 The lead TDO inhibitor molecule is compound 4 (680C91; 6-fluoro-3-[(1ε)-2-(3-pyridinyl)ethenyl]-1H-indole; K i = 51 nM [51] ), and the development of orally available indole derivatives have also been reported [52] , including compound 5 (LM10; 6-fluoro-3-[(E)-2-(1H-tetrazol-5-yl)vinyl]-1H-indole) with the most promising profile (K i = 5.5 μM). LM10 appears to be effective in preclinical use. [53] The role of IDO/TDO inhibition in neurodegenerative disorders where alterations have been published is not as deeply explored as in case of malignancy. Compound 6 (coptisine chloride; 6,7-dihydro-bis(1,3)benzodioxolo[5,6-a:4',5'-g]quinolizinium chloride; IC 50 = 6.3 μM), a component of a traditional Chinese medication Oren-gedoku-to has been reported to be beneficial in a murine model of AD. [54] On the other hand, genetic inhibition of TDO has been shown to ameliorate the phenotype of a transgenic Drosophila model of HD [55] and similarly, genetic inhibition of IDO was protective against QUIN-induced striatal neurotoxicity in mice. [56] Furthermore, inhibition of IDO with compound 1 abrogated systemic inflammation-induced depressive behavior in mice. [57, 58] The genetic ablation or compound 1-induced inhibition of IDO in mice; however, did not influence infarct size and overall outcome in an acute stroke model of mice. [59] Further research is needed to establish the therapeutic potential of IDO/TDO inhibition in disorders associated with neurodegeneration and/or neuronal dysfunction. The structure of the above-mentioned inhibitors of IDO and TDO are demonstrated in Figure 2. 
Kynurenine aminotransferases
There are four subtypes of kynurenine aminotransferases (KATs, EC: 2.6.1.x; reviewed in [60] : KAT-I-II, [61] KAT-III, [62] and mitochondrial aspartate aminotransferase (mitAAT, also called KAT-IV) [63] ). KATs belong to the α-family of pyridoxal-5'-phosphate (PLP)-dependent enzymes, and they are responsible for the irreversible transamination of L-KYN resulting in the production of KYNA. The KATs are abundantly expressed in astrocytes, [64] and the expression of KAT-II is confined entirely to these cell types, [65] with only weak granular staining visible in neurons. [66] With regard to the expression level of different KAT subtypes, a difference between species can be observed: KAT-II has been demonstrated to be the main KYNAproducing enzyme in the rat and human brains, while in the mouse brain mitAAT has the highest activity. [63] However, following the discovery that the neglected role of KAT-I under physiological conditions can be attributed to methodological reasons, it can be assumed that KAT-I may also contribute to the in vivo formation of KYNA. [60] In addition to the assessment of the pathobiochemistry of the KYN pathway, in light of the fact that genetic elimination of KAT-II can improve cognitive functioning, [31] the development of KAT inhibitors may have therapeutic potential, as well. [4, 67] The rationale of a potential therapeutic improvement of cognitive functions in conditions characterized by elevated brain KYNA levels, such as schizophrenia or AD, would be that normalizing KYNA levels would result in the decrease of pathological inhibition of glutamatergic neurotransmission and thereby long-term potentiation, phenomena necessary for memory formation. Studies on the structure function relationship of human KAT-II revealed that within each of the two active sites in the functional dimer the PLP-binding pocket harbors the cofactor molecule in Schiff-base linkage to the ε-amino group of the catalytic residues Lys-263 of the corresponding subunit. [68] These observations in 3D models are essential for drug design targeting the active site of the enzyme. With regard to KAT-II inhibition, non-selective (e.g. compound 7; dichlorovinylcysteine; IC 50 = 30-100 µM [69] ) and selective inhibitors also exist ( Figure 3 ). The spectrum of selective KAT-II inhibitors consists of less potent natural (e.g. compound 8; quisqualic acid; ((2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid); IC 50 = 200-520 µM [69, 70] ), endogenous natural (e.g. compound 9; S-adenosylhomocysteine; IC 50 = 30-100 µM [71] ), and synthetic (e.g. compound 10; 4-carboxy-3-hydroxyphenylglycine; 49% inhibition at 200 µM [70] ), as well as more potent endogenous natural (e.g. compound 11; L-cysteinsulphinic acid; IC 50 = 2 µM [72] ) and synthetic (e.g. compound 12; (S)- (4)-(ethylsulfonyl)benzoylalanine; IC 50 = 6 µM [73] ) substances. Compounds 11 and 12 were demonstrated to be not only pure competitive inhibitors, but also to be substrate analogs. [74] Accordingly the latter one could significantly improve the performance in the Morris water maze cognitive test following intracerebroventricular administration. [75] Furthermore, in addition to the development of secondgeneration drugs with better inhibitory potency (e.g. compound 13; BFF-122; (S)-10-(4-aminopiperazin-1-yl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H- [1, 4] oxazino [2, 3, 4 -ij]quinoline-6-carboxylic acid; 43% inhibition at 1 µM [76] ), there are twoother problems emerging: the penetration through the bloodbrain barrier (BBB) and the observation that sequence variants [80] ). Furthermore, the potency shift between human and rat KAT-II (IC 50 = 263 nM) is considered to be modest, which allows the application of this compound in preclinical rodent models. Similarly to compound 13, compound 15 covalently binds to the enzyme cofactor PLP in the catalytic pocket, creating an irreversible adduct. In addition, the functional triad of the 3-aminohydroxamic acid moiety of compound 15 consists of the H-bond formations of carbonyl oxygen with the side chain of Asn-202 and that of the other oxygen atom in the hydroxamic acid functionality with Arg-399. The structure-activity relationship (SAR) studies with assessing the role of 3-aminohydroxamic acid moiety in inhibitory activity revealed that the (S)-enantiomer is approximately 10-fold more potent compared to the (R)-enantiomer, and the methylation of hydroxamic acid group or the introduction of a methyl group at the C-3 position likewise resulted in a complete loss of activity. Furthermore, the fused phenyl moiety of the molecule contributes to the van der Waals interactions with the hydrophobic pocket of KAT-II formed by Leu-40, Tyr-74, and Leu-293. Preliminary SAR data suggest that substitutions at C-6 and C-7 positions would be used for further optimization of properties. The administration of compound 15 successfully ameliorated ketamine-induced cognitive dysfunction in rats. [81] 2.3. Kynurenine 3-monooxygenase 3-OH-L-KYN is formed by the action of KMO (EC: 1.14.13.9 [82] ). KMO is a flavin adenine dinucleotide (FAD)-containing enzyme localized in the outer mitochondrial membrane. [83] The QUINproducing branch of the kynurenine pathway, including KMO, is mainly localized within microglia and macrophages, [84] which associate the neurodegenerative effects of neurotoxic metabolites with neuroinflammation. Although the expression level of KMO is relatively low in the brain as compared with that in the liver and kidney, [85] [86] [87] the transport of 3-OH-L-KYN through the BBB [88] enables the exertion of its neurotoxic effects in the CNS following a peripheral activation. After L-KYN binding, NADPH reduces FAD before oxygen binding and the formation of L-KYN-FAD-hydroperoxide intermediate.
[89] The next step is the oxidation of L-KYN, yielding 3-OH-L-KYN and water. The demonstration of the 3D enzyme structure [90] would further facilitate the design of KMO inhibitors. The rationale in the development of these inhibitors would be the restoration of the physiological balance in the metabolite levels, i.e. decreasing the production of neurotoxic compounds (such as 3-OH-L-KYN and QUIN) and shifting the pathway into the production of the anti-excitotoxic KYNA, metabolites present in many neurodegenerative diseases in a relative excess and deficit, respectively. [83] Indeed, as the majority of 3-OH-L-KYN is produced in the periphery, the penetration of KMO inhibitors through the BBB is not obligatory. With regard to KMO inhibition, the early attempts resulted in the synthesis of non-selective KMO inhibitors with low potency (e.g. compound 16; nicotinylalanine; IC 50 = 900 µM [91] ) with inhibitory effect on kynureninase as well. However, the addition of compound 16 to L-KYN and probenecid increased the potency to protect against QUINmediated neurotoxicity in the striatum [92] and in the nigrostriatal dopaminergic system. [93] Furthermore, compound 16 has anticonvulsant effects, as well. [91, 94, 95] The development of 4-aryl-4-oxobutanoic acids, such as compound 17 (mNBA; (m-nitrobenzoyl)alanine) resulted in higher potency (IC 50 = 900 nM [96] ) with still non-selective activity. The lead compound 17 exerted protective effects both in vitro (organotypic hippocampal slice cultures) and in vivo (transient bilateral carotid occlusion in gerbils, permanent unilateral middle cerebral artery occlusion in rats) models of cerebral ischemia via the reduction of 3-OH-KYN and the increase in KYNA concentrations. [97] [98] [99] Furthermore, compound 17 could alleviate kainate-induced neurotoxicity, [100] and has anticonvulsant activity, [91] as well. Compound 17 also reduced QUIN formation in immune-activated mice. [101] Compound 18 (PNU 156561, formerly known as FCE 28833A; (R,S)-3,4-dichlorobenzoylalanine) is also capable of exerting anti-ischemic effects, probably via increasing brain KYNA levels. [102, 103] With regard to SAR studies in benzoylalanines, it can be concluded that the S-enantiomers are more potent (IC 50 = 500 nM [104] ), the carboxyl group is obligatory for inhibition, whereas the amine group is not. [105] Therefore, the amine can be replaced with a methylene bridge, resulting in compound 19 (UPF 648; (1S,2S)-2-(3,4-dichlorobenzoyl) cyclopropanecarboxylic acid) with much higher potency (IC 50 = 40 nM) and selectivity. [76, 106] In neuron-depleted striata (7 days following QUIN injection) compound 19 not only decreased 3-OH-KYN and QUIN production (by 77% and 66%, respectively), but moderately increased KYNA synthesis (by 27%) as well, [76] and was proved protective in a QUIN model of HD. [107] Furthermore, compound 19 was protective in a Drosophila model of HD as well. [50] However, the formation of hydrogen peroxide probably via the decay of the intermediate hydroperoxyflavin, would limit the application of these L-KYN-like molecules as KMO inhibitors such as, compound 17 or 19. [90] Sulfonamides are structural analogs of L-KYN as well, containing an FAD-binding benzene ring, a fiveor six-membered aromatic ring as linker, a sulfonamide as amino-acid bioisostere and an extendable benzene ring. [83] The inhibitory potential is a function of the size of the linking ring, ranging from a minimal inhibition in case of six-membered rings (≤25% at 10 µM [108] ) to a significantly more potent inhibition in case of five-membered rings, such as thiazoles. [109] Small substituents, such as methoxy groups, are required on both benzene rings for optimal in vitro binding. Accordingly, the lead compound of phenylthiazole benzenesulfonamides is compound 20 (Ro 61-8048; 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzenesulfonamide; IC 50 = 37 nM). Although drugs belonging to the sulfonamide group of KMO inhibitors have poor penetration through the BBB, this would not necessarily be a problem in light of the abovementioned fact that the majority of 3-OH-L-KYN is produced in the periphery. Accordingly, compound 20 increased the serum levels of KYN and KYNA and decreased the incidence of L-DOPA-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated cynomolgus monkeys, but did not affect the antiparkinsonian effect of L-DOPA. [110, 111] Compound 20 successfully improved dystonia in a genetic model of paroxysmal dyskinesias. [112, 113] With regard to HD, compound 20 was proved protective in yeast and Drosophila models of the disease. [55, 114] Furthermore, similarly to compound 17, compound 20 reduced QUIN formation in immune-activated mice [101] and also exerted protective effects in both in vitro and in vivo models of cerebral ischemia via the reduction of 3-OH-KYN and the increase in KYNA concentrations. [97] [98] [99] Similarly to compound 16, compound 20 proved to have anticonvulsant effects. [91] Furthermore, compound 20 exerted substantial anti-inflammatory effects in animal models of cerebral malaria and trypanosomiasis. [115, 116] To overcome the problem that compound 20 is a metabolically unstable compound, a potential slow-release prodrug, compound 21 (JM6; 2-(3,4-dimethoxybenzene-sulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl)-methylthiazole) were developed. Although it successfully ameliorated the neurodegenerative processes in the R6/2 transgenic mouse model of HD and a transgenic mouse model of AD overexpressing human amyloid precursor protein, [117] later the validity of these results has been criticized in light of pharmacokinetic studies that compound 21 is neither a prodrug for compound 20 nor a potent KMO inhibitor. [118] Aryl pyrimidines would be promising candidates as KMO inhibitors, as well [119] (SAR to be detailed later). 4-Aryl-oxobutanoates and their esters (e.g. 
Kynureninase
Kynureninase (EC: 3.7.1.3), similarly to KATs, is a PLP-dependent enzyme, as well. It is responsible for the β,γ-hydrolytic cleavage of 3-OH-L-KYN (human and other eukaryotic constitutive kynureninases) and L-KYN (many prokaryotic inducible kynureninases), resulting in the formation of 3-OH-ANA or anthranilic acid, respectively, and L-alanine. [122] With regard to the structure of human recombinant kynureninase, the enzyme possesses two substrate binding sites: a regulatory non-catalytic site and a catalytic site. [123] The explanation for the possibility of two substrates despite the highly conserved active sites would be a slight difference in enzyme structure due to conserved point mutations, as demonstrated by 3D models. [124] In prokaryotes, the Trp69 side chain phenyl group γ-carbon of Thr282 form a hydrophobic patch which is unfavorable for hydrogen binding with the 3-hydroxyl group of 3-OH-L-KYN. Conversely, in eukaryotes, the side chain of His102 and the δ nitrogen of Asn333 promote that interaction. With regard to the expression pattern of human kynureninase in extrahepatic cells, it is mainly expressed in macrophages and microglia, similarly to KMO. [84] In addition to the above-mentioned non-selective inhibitors, such as compound 16 (IC 50 = 800 µM [91] ) and compound 17 (IC 50 = 100 µM [96] ), some more potent and selective compounds exist ( Figure 5 ). With regard to SAR studies in a structural analog of L-KYN, compound 24 (2-amino-4-(3-hydroxyphenyl)-4-hydroxybutanoic acid; (K i = 40 and 100 nM for recombinant human or rat hepatic kynureninase, respectively [125, 126] ), revealed that the 2-amino group is crucial for activity, whereas the 3-hydroxyl group plays an important role in binding at the active site of kynureninase, presumably via hydrogen bonding. 2-Amino-S-aryl-cysteine-S,S-dioxides (the most potent is compound 25; 2-amino-5-methyl-S-phenyl cysteine S,S-dioxide; IC 50 = 11 µM) would present another option for the selective inhibition of kynureninase.
[127] The 2-amino moiety appears to be essential for enzyme inhibition because neither of the 2-nitro-substituted compounds exerted inhibitory activity. With regard to the inhibition of kynureninase from Pseudomonas fluorescens, brominated compounds, such as compound 26 ((4R)-5-bromodihydro-L-kynurenine; K i = 55 nM) with slow substrate activity, have been synthesized as well. [128] The (4S)-epimer is also a potent inhibitor (K i = 170 nM) with no demonstrated substrate activity.
3-Hydroxyanthranilate 3,4-dioxygenase
3-Hydroxyanthranilate 3,4-dioxygenase (3-HAO, EC: 1.13.11.6) is responsible for the formation of QUIN from 3-OH-ANA. [129] 3-HAO, as demonstrated by 3D models as well, is a cytosolic homodimer protein, with each subunit containing two nonheme ferrous irons, and it catalyzes the cleavage of the benzene ring of 3-OH-ANA. [130, 131] The direct product of this reaction is an intermediate, α-amino-β-carboxymuconic acid ε-semialdehyde. This unstable compound can either spontaneously arrange to QUIN or can be converted to picolinic acid after decarboxylation. 3-HAO is mainly localized in the liver and kidney, but is also present in the CNS in low amounts. [129, 132] With regard to CNS, the main source of 3-HAO, being the part of the QUIN-producing branch of the KYN Figure 4 can also exert inhibitory effect on kynureninase.
pathway, are microglia [84] ; however, it is also expressed by astrocytes. [64] Following the early exploration of weak inhibitors of 3-HAO, such as compound 27 (m-hydroxybenzoic acid; IC 50 = 480 µM [133] ), more potent compounds have been developed later ( Figure 6 ). The systemic administration of 4-chloro-L-KYN (4-Cl-L-KYN), the BBB-penetrable pro-drug of 7-Cl-KYNA, a molecule exerting enhanced antagonism at the glycine/NMDA receptors, resulted in the prevention of QUIN-and malonate-induced neurotoxicity in the rat striatum. [134] 4-Cl-L-KYN is metabolized to compound 28 (4-chloro-3-hydroxyanthranilic acid), an inhibitor of QUIN synthesis (IC 50 = 32 µM [135] [136] [137] ), which may further broaden the possibility for neuroprotection. Compound 28 successfully improved functional recovery and preserved white matter after spinal cord injury in adult Hartley guinea pigs. [138] 4,5-Disubstituted, 4,6-disubstituted, and 4,5,6-trisubstituted 3-OH-ANA derivatives were also synthesized and demonstrated to have inhibitory action on 3-HAO. [139] The positioning of electron withdrawing groups in the 4-and 5-positions increased the potency of enzyme inhibition. NCR-631 is also a 3-hydroxyanthranilate analog (structure is not available), which exerted protective effects against anoxia and neuroinflammation-related damage [140] and demonstrated anticonvulsant effects, as well. [141] 2-Aminonicotinic acid 1-oxides, e.g. compound 29 (6-methyl-2-aminonicotinic acid 1-oxide; IC 50 = 1.1 µM), represent another promising group with inhibitory activity on 3-HAO. [142] Although the inhibitors of both kynureninase and 3-HAO would yield interesting compounds for future drug development, they are currently not in the pipeline with regard to the modulation of TRP metabolism in neurotherapeutic aspect.
Kynurenine pathway inhibitors: advances in the recent patent literature (2012-2015)
Thomson Innovation Patent Export was utilized to search for patents with the demonstration of inhibitors of the kynurenine pathway as neurotherapeutics applying the assessment period of 2012-2015. Twenty patents were found, out of which EP2664615 [143] was excluded because the invention related to novel compounds for the inhibition of glycogen synthase kinase-3β and/or modulation of NMDA channel activity, not for the inhibition of enzymes of the kynurenine pathway. There were several overlaps among the remaining 19 patents, due to the publication of the same inventions under the egis of World Intellectual Property Organization, United States Patent and Trademark Office and European Patent Office. Therefore, finally, 11 inventions could be identified out of which one deals with the inhibitors of IDO1, IDO2, and TDO, and the remaining deal with the inhibitors of KMO. were applied orally following intraperitoneal lipopolysaccharide injection into mice to model immune activation and to study IDO1 expression and activity. Plasma KYN levels were measured as the biochemical indicator of decreased IDO activity. The use of compounds 30, 35, 36, and 37 resulted in a reduction more than 50% in KYN level, whereas compound 31 resulted in a reduction of between 25% and 50%. Compounds 30, 35, 36 , and 37 significantly decreased tumor growth following oral administration when CT-26 mouse colorectal tumor forming cells were injected subcutaneously in the right flank of Balb/c mice. With regard to the effect on KYN levels in plasma and tumor tissue, compound 30 induced an 81% and a 62% decrease, respectively, whereas compound 35 induced an 81% and a 67% decrease, respectively. Compounds 30 and 35 proved capable of penetrating the BBB following intravenous injection, indicating that these compounds can be useful for IDO or TDO-associated brain diseases as well.
Kynurenine 3-monooxygenase

Aryl pyrimidines
As mentioned above, aryl pyrimidines would be promising candidates of KMO inhibition (Figure 8) . [113] The patent documents US20130029988 [145] (WO2011091153, EP252844), US201 30331370 [146] (WO2010017179, EP2331095), WO2013016488 [147] (US20140329816, EP2736337), WO2013033068 [148] (US20140329795, EP2751086), and WO2013033085 [149] (EP2750677) also deal with inventions in the field of aryl pyrimidines as KMO inhibitors. The aryl pyrimidine skeleton was proposed on the basis that the pyrimidine N-3 nitrogen would mimic the carbonyl oxygen of L-KYN and some of its analogs (compounds 17 and 19), whereas the N-1 nitrogen would mimic the amino group of the above-mentioned compounds. [119] The above-mentioned patent documents and the comprehensive work of Toledo-Sherman et al. [119] delineate the effects of modifications of the aryl ring at the C-4 position, substituents at the pyrimidine core, carboxylic acid modifications (mainly via esterification or amidation), the application of acid bioisosteres and the non-acidic replacement at the C-6 position on inhibitory potency of the molecule. The inhibitory potency was tested via the application of biochemical assays using mitochondrial fractions derived from mice, rats, and human liver tissues and via the application of cellular assays using CHO cell lines expressing human or rodent KMO enzymes and the physiologically more relevant primary cells with endogenous levels of KMO. The level of inhibition was expressed either as the percentage of inhibition at 10 µM concentration of the tested compounds or as IC 50 values. With regard to the modifications of the aryl ring at the C-4 position, compound 41 (4-(3,4-dichlorophenyl)-pyrimidine-6-carboxylic acid; 105.5%, IC 50 = 0.6 nM) and compound 42 (4-(3-chlorophenyl)-pyrimidine-6-carboxylic acid; 105.6%, IC 50 = 0.5 nM) serve as lead compounds with excellent inhibitory potency. The removal of chlorines (compound
43;
4-phenyl-pyrimidine-6-carboxylic acid; IC 50 = 38 nM), the saturation of the phenyl ring (compound 44; 4-cyclohexyl-pyrimidine-6-carboxylic acid; IC 50 = 340 nM) the replacement of the phenyl ring with a heteroaryl ring (e.g. compound 45; 4-pyridine-3-yl-pyrimidine-6-carboxylic acid; IC 50 = 990 nM) and the introduction of large substituents (e.g. compound 46; 4-biphenyl-3-yl-pyrimidine-6-carboxylic acid; 70%, IC 50 = 2.13 µM) similarly resulted in substantial decrease in inhibitory potency. The application of methyl group at the C-2 position in compound 41 or compound 47 (2-[6-(3,4-dichlorophenyl)pyrimidin-4-yl]-4-methyl-oxazole; 100.65%) considerably reduced the potency of inhibition (compound 48; 4-(3,4-dichlorophenyl)-2-methyl-pyrimidine-6-carboxylic acid; IC 50 = 12 nM; compound 49; 2-[6-(3,4-dichlorophenyl)-2-methyl-pyrimidin-4-yl]-4-methyloxazole; 46.84%) which can be attributed to steric properties interfering with the hydrogen bonding interaction of KMO with the N-1 nitrogen. The application of a methyl group at the C-5 position in compound 41 also considerably decreased the potency of inhibition (compound 50; 4-(3,4-dichlorophenyl)-5-methyl-pyrimidine-6-carboxylic acid; IC 50 = 10 nM), probably due to disturbing the co-planarity of the biaryl ring system via posing substantial strain on ring torsions. Although the penetration of the BBB is not obligatory in case of KMO inhibitors, it would broaden the mechanism of action by local CNS effects. The presence of carboxylic acid moiety is critical to form an ionic salt bridge with a guanidinium moiety of an arginine of KMO; however, it considerably decreases the penetration through the BBB. It seems that esterification (e.g. compound 51; isopropyl-6-(3,4-dichlorophenyl)pyrimidine-4-carboxylate; 100%) or amidation (e.g. compound 52; 6-(3,4-dichlorophenyl)-N-methyl-pyrimidine-4-carboxamide; 100.31%) retains the inhibitory potential of the majority of molecules; however, it depends on the side-chain with some exceptions (e.g. compound 53; N-(2-amino-1-methyl-2-oxo-ethyl)-6-(3,4-dichlorophenyl)pyrimidine-4-carboxamide; 47.73%). With regard to the application of acid bio-isosteres, such as 1H-tetrazole (compound 54; 4-(3,4-dichlorophenyl)-6-(1H-tetrazol-5-yl)pyrimidine; 102.87%, IC 50 = 2 nM), oxadiazolone (compound 55; 3-[4-(3,4-dichlorophenyl)pyrimidin-6-yl]-4H-1,2,4- oxadiazol-5-one; 101.78%, IC 50 . compound 56; N-[4-(3,4-dichlorophenyl)pyrimidine-6 carbonyl]-benzenesulfonamide; 100.73%, IC 50 = 25 nM) at the C-6 position in 3,4-dichlorophenyl-substituted molecules at the C-4 position resulted in retained inhibition of KMO. However, non-acidic replacement with moieties, such as carbonitrile (compound 57; 4-(3,4-dichlorophenyl)pyrimidine-6-carbonitrile; 68.36%, IC 50 = 4 µM), 1,2,4-oxadiazole (compound 58; 4-(3,4-dichlorophenyl)-6-(1,2,4-oxadizol-3-yl)pyrimidine; 68.52%, IC 50 = 5.06 µM), thiazole (compound 59; 4-(3,4-dichlorophenyl)-6-thiazol-2-yl)pyrimidine; 48%), or 1H-pyrazole (compound 60; 4-(3,4-dichlorophenyl)-6-(1H-pyrazol-3-yl)pyrimidine; 19%) provided decreased potency of inhibition. As substitution of the pyrimidine moiety at the C-6 position is restricted, further optimization of BBB penetration with retained KMO inhibition has been proposed via the substitutions in the phenyl ring. Accordingly, compound 61 (4-(3-chloro-4-cyclopropoxy-phenyl)-pyrimidine-6-carboxylic acid; 100%, IC 50 = 0.5 nM) could be detected in brain tissues following intravenous or per os administration as well, and exerted profound elevation in extracellular KYN, anthranilic acid, and KYNA levels.
Pyrimidine benzenesulfonamides
In addition to the delineation of pyrimidine carboxylic acids, the patent document WO2013033085 [149] 
Phenylthiazole benzenesulfonamides
US8710237 [150] (priority publications: WO2008022281, US20120022052, EP2054397) reports experimental data on phenylthiazole benzenesulfonamides (Figure 10 ), including compounds 20 and 21. Although the validity of results demonstrating the beneficial effects of compound 21 has been criticized in light of pharmacokinetic studies that compound 21 is neither a prodrug for compound 20 nor a potent KMO inhibitor [118] , the invention reports several other compounds with promising inhibitory effects. The percentage of inhibition at 10 µM concentration of the tested compounds applying rat liver homogenates has been investigated in some molecules. With regard to SAR, the effects of substitution at the nitrogen of sulfonamide moiety and at the C-5 position of thiazole moiety were assessed. Compound 67 significantly decreased the brain concentrations of 3-OH-KYN and QUIN levels in a dose-dependent manner 5 h following intraperitoneal administration, while Compound 68 and 69 only decreased 3-OH-KYN concentrations. Nevertheless, these drugs did not affect the levels of either brain or plasma KYN and KYNA. In light of its inhibitory potency, the above-mentioned effect of compound 69 is surprising, and it would be attributed to prodrug properties.
Phenylthiadiazole benzenesulfonamides
The patent document US20120046324 [151] (EP2420494, WO2008022286) reports some scientific data on the assessment of phenylthiadiazole benzenesulfonamides (Figure 11 ). In light of the percentage of inhibition at 10 µM, it can be concluded that the application of 1,2,4-thiadiazole moiety (e.g. Figure 9 . Some pyrimidine benzenesulfonamides as inhibitors of kynurenine 3-monooxygenase. 
trans-2-Substituted-cyclopropane-1-carboxylic acids
The further development of trans-2-substituted-cyclopropane-1-carboxylic acids is based on the promising preclinical data obtained from the experiments with compound 19. The patent documents WO2013151707 [152] (EP2833879, US20150057238) and WO2015047978 [153] report molecules developed either as a result of modification of the benzoyl ring or further substitution of the cyclopropane moiety, or the modification of carboxylic acid moiety via amidation or application of acid bioisosteres ( Figure 12 ). In light of the percentage of inhibition at 30 µM, it can be concluded that modification of the benzoyl ring did not considerably influence the inhibitory potential (e.g. compound 72;
(1S,2S)-2-(7-chloro-2,3-dihydro-1-benzofuran-5-carbonyl) cyclopropane-1-carboxylic acid; 100.3%). The methyl-substitution of cyclopropane moiety was assessed, as well. The application of a methyl group at the C-1 position did not considerably affect the inhibitory potency (compound 73; (1S,2S)-2-(3,4-dichlorobenzoyl)-1-methylcyclopropane-1-carboxylic acid; 98.6%). However, when this methyl group was introduced at the C-3 position, its effects depended on steric conditions (com- 
Isoxazoles and isoxazolines
The patent document US20120329812 [154] acetic acid; 101.21%). Although esterification did not influence the activity (e.g. compound 85; [3-(3,4-dichlorophenyl) 
Conclusions
Certain enzymes of the KYN pathway of TRP metabolism, especially those having a central initiating role in the pathway (such as IDO and TDO) or that are responsible for the formation of neuroactive kynurenines (such as KATs, KMO, kynureninase, and 3-HAO) serve as interesting targets for pharmaceutical drug design, in light of the involvement of the alterations of the pathway in numerous disorders, including neurological conditions. There has been a considerable development in this field in recent decades with emerging preclinical data supporting the beneficial effects of these compounds. Although there is a constant need for further development of lead compounds to achieve drugs with appropriate effect/side-effect profile, some of the available substances are already worth testing in clinical trials.
Expert opinion
In recent years, numerous research has been done to explore the involvement of TRP metabolism in neurological and psychiatric disorders. Although clinical and preclinical data are reassuring and yield several possibilities for therapeutic intervention, there is a paucity of applicable drugs in daily clinical practice. With regard to KYNA derivatives, most of them, such as GV150526 in stroke, [155] were unable to exert significant improvement in clinical outcome. However, there are some other promising candidates, including halogenated compounds and KYNA amides, which could be utilized in future clinical studies. [4, 67, 156, 157] 4-Cl-KYN (also known as AV-101), the BBB-penetrable prodrug of 7-Cl-KYNA, a molecule demonstrating enhanced antagonism at glycine/NMDA receptors, was successfully assessed in a phase I trial (ClinicalTrials.gov identifier: NCT01483846) and an investigational new drug application for neuropathic pain has been filed with the US Food and Drug Administration. Furthermore, there is an ongoing recruitment for a trial assessing the therapeutic potential of this drug in major depressive disorder (ClinicalTrials.gov identifier: NCT02484456). With regard to the metabolic shift concept with the aim of reversing pathological alterations at the level of neuroactive compounds of the KYN pathway of TRP metabolism, several enzyme inhibitors have been developed. The determination of enzyme structures considerably promoted the development of potent inhibitors; most of them were designed as a structural analog of the natural enzyme substrate. As IDO/TDO activation would serve as a double-edged sword in the CNS, i.e. protective immunosuppressive response versus considerable elevation in the levels of cytotoxic TRP metabolites, the manipulation of these enzymes should be implemented very cautiously. Nevertheless, compounds 1 and 2 seem to be beneficial in preclinical studies on their antitumor effect. The enrollment of patients in a phase I/II study assessing the efficacy of compound 1 in combination with temozolomide in primary malignant brain tumors is ongoing (ClinicalTrials.gov identifier: NCT02052648). In light of recent preclinical data with 2,3-diamino-furo[2,3-c]pyridine and 2,3-diamino-benzo[b]thiophene derivatives, these compounds deserve attention for future clinical studies as well. Although most neurological disorders can be characterized by the relative deficiency of the neuroprotectant KYNA, the excessive elevation of this compound may result in deteriorated cognitive functions. Therefore, the application of KAT inhibitors in these conditions, such as schizophrenia, would have justification. Although compounds 13, 14, and 15 all have promising preclinical properties, there are no clinical studies ongoing with KAT inhibitors. Probably the hottest topic in the field of inhibitors of KYN pathway as neurotherapeutics is the development of KMO inhibitors with the aim of reducing the levels of toxic compounds and shifting the pathway toward the production of neuroprotective KYNA to restore the balance of altered metabolite levels. Although compound 19 and substances achieved from the further development of trans-2-substituted-cyclopropane-1-carboxylic acids provided reassuring preclinical data, there are currently no clinical trials ongoing with any of these compounds. Furthermore, the situation is the same with the more potent phenylthiazole benzenesulfonamides, including compound 20, phenylthiadiazole benzenesulfonamides, isoxazoles and isoxazolines. The advanced development of aryl pyrimidines and pyrimidine benzenesulfonamides based on well-designed SAR studies in recent years holds the promise of development of potent and selective compounds. Hopefully, some of these molecules would be appropriate for future clinical testing if sufficient reassuring preclinical data were gathered. Although promising kynureninase and 3-HAO inhibitors also exist, currently the design of KMO inhibitors seems to be the pipeline of drug development with the aim of the reduction of the levels of neurotoxic compounds of the KYN pathway. With regard to future research in this field, in addition to the development of drugs with much higher selectivity, enhanced potency and better side-effect profile, a special attention should also be paid to the better characterization of neurochemical alterations and the exploration of possible genetic background to enable the establishment of the best individualized therapy. with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
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